Tecentriq Market demand is shaped by the use of atezolizumab in selected cases of triple-negative breast cancer. Its use with nab-paclitaxel depends on the applicable indication and relevant biomarker and treatment eligibility criteria.
The Tecentriq Market size is projected to reach US$ 12.55 million by 2034 from US$ 4.29 million in 2025. The market is anticipated to register a CAGR of 12.65%...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek